{"id":419,"date":"2023-08-25T14:01:40","date_gmt":"2023-08-25T06:01:40","guid":{"rendered":"https:\/\/consulting-hmk.com\/?p=419"},"modified":"2024-01-18T09:52:31","modified_gmt":"2024-01-18T01:52:31","slug":"anaprazole-sodium-enteric-coated-tablets-approved-for-marketing-by-china-nmpa","status":"publish","type":"post","link":"https:\/\/www.consulting-hmk.com\/pt\/anaprazole-sodium-enteric-coated-tablets-approved-for-marketing-by-china-nmpa\/","title":{"rendered":"Anaprazole Sodium Enteric-coated Tablets aprovado para comercializa\u00e7\u00e3o pela China NMPA"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0 \u00a0 \u00a0 Recentemente, o medicamento inovador de categoria 1 \"Anaprazole Sodium Enteric-coated Tablets\" (designa\u00e7\u00e3o comercial chinesa: \u5b89\u4e45\u536b) da Xuanzhu (Beijing) Pharmaceutical Technology Co., Ltd. foi aprovado pela China NMPA. \u00c9 um medicamento inovador desenvolvido de forma independente na China e tem direitos de propriedade intelectual independentes, indicado para o tratamento de \u00falceras duodenais.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-412 aligncenter\" title=\"Anaprazole Sodium Enteric-coated Tablets aprovado para comercializa\u00e7\u00e3o pela China NMPA\" src=\"https:\/\/consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-300x240.jpg\" alt=\"Anaprazole Sodium Enteric-coated Tablets aprovado para comercializa\u00e7\u00e3o pela China NMPA\" width=\"575\" height=\"460\" srcset=\"https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-300x240.jpg 300w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-1024x819.jpg 1024w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-768x614.jpg 768w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-1536x1229.jpg 1536w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-2048x1638.jpg 2048w\" sizes=\"(max-width: 575px) 100vw, 575px\" \/><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">O anaprazol \u00e9 um inibidor da bomba de prot\u00f5es e pertence aos compostos de benzimidazol. Pode inibir a secre\u00e7\u00e3o de \u00e1cido g\u00e1strico atrav\u00e9s da inibi\u00e7\u00e3o da atividade enzim\u00e1tica do H+- K+-ATP da c\u00e9lula parietal e da redu\u00e7\u00e3o da capacidade de transporte de prot\u00f5es. A comercializa\u00e7\u00e3o deste medicamento proporciona novas op\u00e7\u00f5es de tratamento para os doentes com \u00falceras duodenais.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Recentemente, o medicamento inovador de categoria 1 Anaprazole Sodium Enteric-coated Tablets da Xuanzhu (Beijing) Pharmaceutical Technology Co., Ltd. foi aprovado pela China NMPA. Trata-se de um medicamento inovador desenvolvido de forma independente na China e com direitos de propriedade intelectual independentes, indicado para o tratamento de \u00falceras duodenais.<\/p>","protected":false},"author":4,"featured_media":420,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[70],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/posts\/419"}],"collection":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/comments?post=419"}],"version-history":[{"count":0,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/posts\/419\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/media\/420"}],"wp:attachment":[{"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/media?parent=419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/categories?post=419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/pt\/wp-json\/wp\/v2\/tags?post=419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}